NCT07608835 IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy
| NCT ID | NCT07608835 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Paoli-Calmettes |
| Condition | Non-small Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-02-12 |
| Primary Completion | 2033-05-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2026-02-12 with a primary completion date of 2033-05-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents. This research aims to identify biomarkers of response to immunotherapy at the tumor level and to characterize new therapeutic targets
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years or older, male or female. * Willing to participate in the study and having signed a written informed consent form. * Presenting a strong suspicion of localized resectable or advanced unresectable non-small cell lung cancer, or having a histologically confirmed non-small cell lung cancer. * Affiliated with a social security system or benefiting from such a system. Exclusion Criteria: * Individuals in an emergency situation, adults under legal protection (guardianship, curatorship, or judicial protection), or individuals unable to provide informed consent. * Inability to comply with the medical follow-up required by the study for geographical, social, or psychological reasons. * History of solid organ transplantation or hematopoietic stem cell transplantation. * Pregnant or breastfeeding women.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07608835 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07608835 currently recruiting?
Yes, NCT07608835 is actively recruiting participants. Contact the research team at pakradounij@ipc.unicancer.fr for enrollment information.
Where is the NCT07608835 trial being conducted?
This trial is being conducted at Marseille, France.
Who is sponsoring the NCT07608835 clinical trial?
NCT07608835 is sponsored by Institut Paoli-Calmettes. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.